SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT- ACCEPTANCE OF THE NEW DRUG APPLICATION FOR SENAPARIB AS THE MAINTENANCE TREATMENT FOLLOWING FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 25 August 2023.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.* (上海君派英實藥業有限公司) ("**Junpai Yingshi**"), a company jointly invested by the Company and Impact Therapeutics (Shanghai), Inc.* (上海瑛派藥業有限公司) ("**Impact Shanghai**"), has received the Acceptance Notice (《受理通知書》) issued by the National Medical Products Administration. The new drug application for poly (ADP-ribose) polymerase ("**PARP**") inhibitor senaparib (product code: JS109/IMP4297), as maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics ("**FIGO**") stage III-IV epithelial ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer, who have had a complete response or partial response, has been accepted.

ABOUT SENAPARIB

Drug name: IMP4297 capsule
Application matter: Registration of Domestic Production of Pharmaceutical Product
Acceptance No.: CXHS2300073
Applicant: Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.*
Review conclusion: Following the review, the application is accepted pursuant to Article 32 of the Administrative License Law of the People's Republic of China* (《中華人民共和國行政許可法》).

Established in September 2020, Junpai Yingshi is owned 50% by the Company and 50% by Impact Shanghai, a wholly-owned subsidiary of IMPACT Therapeutics, Inc.* (南京英派藥業有限公司). The joint venture company has the right to research, develop and commercialise senaparib, a novel targeted anti-tumor drug, in mainland China, Hong Kong and the Macau Special Administrative Region. Senaparib is a PARP inhibitor supported by the national special project for innovative manufacturing of major new drugs under the 13th Five-Year Plan, with inspection and acceptance

having completed smoothly. In August 2022, the fixed dose combination capsules of senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration.

Ovarian cancer is one of the most common lethal female genital tract malignant tumor. According to GLOBOCAN 2020 data, there were around 310,000 new cases of ovarian cancer every year across the world, with around 210,000 death cases every year. As the early symptoms of ovarian cancer are hidden and non-specific, around 80% of patients are diagnosed with ovarian cancer at an advanced stage, with five-year survival rate of only 40%. Although ovarian cancer can be relieved following primary platinum-based chemotherapy, most of the patients suffer inevitable cancer relapse. Over the years, PARP inhibitor is changing the treatment trend for ovarian cancer. In particular, its maintenance treatment can extend the response time following first-line platinum-based chemotherapy and delay cancer relapse.

The new drug application is based primarily on the FLAMES study (NCT04169997), a randomized, double-blind, placebo-controlled, multi-center phase III clinical study aiming to evaluate the efficacy and safety of senaparib following first-line platinum-based chemotherapy in the monotherapy maintenance treatment of patients with FIGO stage III-IV ovarian cancer who have had a complete response (CR) or partial response (PR). The results of the interim analysis of the FLAMES study demonstrated that senaparib can significantly prolong the progression-free survival (PFS) of patients with advanced ovarian cancer, and patients can benefit regardless of the expression of the breast cancer susceptibility gene (BRCA).

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict accordance with relevant regulations.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 25 August 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Wu Hai and Mr. Tang Yi as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*